Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView”
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
Search
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Boehringer Ingelheim today reported a strong performance in 2022
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
Therapeutics
Therapeutics
Lameness – a common problem in horses
The causes of lameness, and why there is a clear need for innovation and new treatment options.
Corporate Profile
Corporate Profile
More Cherished Moments
Innovation in healthcare is about more than just a new approach or technology. We innovate for better health of people and animals.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
FuturePack
Boehringer Ingelheim has built a new special machine that enables efficient and sustainable packaging of small batches.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Grass Roots Events 2022
View our list of Grass Roots events in 2022 and find an event near you.
We’re All In
Watch our video to learn about our approach to innovation and partnerships
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
World Recycling Day: Closing the Loop
Transitioning the economy from a linear to a circular approach herculean task – but also an innovation that carries huge potential
Retinal health
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
All the same, yet different – Ethnic Equality Month
Mohammed Samy, Human Pharma Marketing Team Lead from Amsterdam explains how ethnic diversity creates collective strength and sustainable growth
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines in Algeria
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future
Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.